Back to Search
Start Over
Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.
- Source :
-
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology [J Neuroimmune Pharmacol] 2019 Jun; Vol. 14 (2), pp. 295-311. Date of Electronic Publication: 2018 Nov 28. - Publication Year :
- 2019
-
Abstract
- Cortical cerebral ischemia elicits neuroinflammation as well as secondary neuronal degeneration in remote areas. Locally distinct and specific secondary neurodegeneration affecting thalamic nuclei connected to cortical areas highlights such processes. Osteopontin (OPN) is a cytokine-like glycoprotein that is excreted in high amounts after cerebral ischemia and exerts various immunomodulatory functions. We here examined putative protective effects of OPN in secondary thalamic degeneration. We subjected male Wistar rats to photothrombosis and subsequently injected OPN or placebo intracerebroventricularly. Immunohistochemical and fluorescence staining was used to detect the extent of neuronal degeneration and microglia activation. Ex vivo autoradiography with radiotracers available for human in vivo PET studies, i.e., CIS-4-[ <superscript>18</superscript> F]Fluor-D-Proline (D-cis-[ <superscript>18</superscript> F]FPRO), and [6- <superscript>3</superscript> H]thymidine ([ <superscript>3</superscript> H]thymidine), confirmed degeneration and proliferation, respectively. We found secondary neurodegeneration in the thalamus characterized by microglial activation and neuronal loss. Neuronal loss was restricted to areas of microglial infiltration. Treatment with OPN significantly decreased neurodegeneration, inflammation and microglial proliferation. Microglia displayed morphological signs of activation without expressing markers of M1 or M2 polarization. D-CIS-[ <superscript>18</superscript> F]FPRO-uptake mirrored attenuated degeneration in OPN-treated animals. Notably, [ <superscript>3</superscript> H]thymidine and BrdU-staining revealed increased stem cell proliferation after treatment with OPN. The data suggest that OPN is able to ameliorate secondary neurodegeneration in thalamic nuclei. These effects can be visualized by radiotracers D-CIS-[ <superscript>18</superscript> F]FPRO and [ <superscript>3</superscript> H]thymidine, opening new vistas for translational studies. Graphical Abstract Intracerebroventricular injection of osteopontin attenuates thalamic degeneration after cortical ischemia (pink area). Disruption of thalamocortical connections (blue) and degeneration of thalamic nuclei (encircled) leads to microglia activation. Osteopontin protects from both neurodegeneration and microglia activation as assessed by histological analysis and autoradiograpic studies.
- Subjects :
- Animals
Brain Ischemia pathology
Macrophage Activation drug effects
Male
Microglia drug effects
Neurodegenerative Diseases diagnostic imaging
Neurodegenerative Diseases pathology
Neurons pathology
Phagocytes drug effects
Phagocytes pathology
Positron-Emission Tomography
Rats
Rats, Wistar
Stroke complications
Stroke diagnostic imaging
Thalamic Diseases diagnostic imaging
Thalamic Diseases pathology
Thalamus diagnostic imaging
Thrombosis pathology
Neurodegenerative Diseases prevention & control
Osteopontin pharmacology
Stroke pathology
Thalamic Diseases prevention & control
Thalamus pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1557-1904
- Volume :
- 14
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 30488353
- Full Text :
- https://doi.org/10.1007/s11481-018-9826-1